EGFR and small cell lung carcinoma: Dual p53/RB inactivation is ubiquitous in SCLC (Peifer et al., 2012; George et al., 2015), and EGFR-mutant LUADs with p53/RB loss are more likely to undergo SCLC transformation after TKI treatment (Offin et al., 2019; Niederst et al., 2015; Lee et al., 2017).